3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Motor Activity
30
Breast Neoplasms
19
Neoplasms
13
Prostatic Neoplasms
10
Obesity
6
Colorectal Neoplasms
6
Sarcopenia
5
Pancreatic Neoplasms
5
Lung Neoplasms
4
Signs and Symptoms
3
Polycystic Ovary Syndrome
3
Multiple Myeloma
3
Lymphedema
3
Inflammation
3
Head and Neck Neoplasms
3
Fatigue
3
Diabetes Mellitus, Type 2
3
Colonic Neoplasms
3
Brain Neoplasms
3
Uterine Cervical Neoplasms
2
Osteoporosis, Postmenopausal
2
Osteoporosis
2
Lymphoma
2
Leukemia
2
Diabetes Mellitus
2
Carcinoma, Non-Small-Cell Lung
2
Cachexia
2
Weight Loss
1
Uterine Neoplasms
1
Urinary Incontinence
1
Interventions
fludarabine
2
Cyclophosphamide
2
zanubrutinib
1
pegfilgrastim
1
obinutuzumab
1
fludarabine phosphate
1
Specimen Handling
1
Resistance Training
1
Radiotherapy
1
Neuropsychological Tests
1
Modafinil
1
Magnetic Resonance Spectroscopy
1
Lenalidomide
1
Injections
1
Filgrastim
1
Contrast Media
1
Blood Specimen Collection
1
Azacitidine
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase NA
×
Lymphoma, B-Cell
×
Resistance Training
×
Clear all
NCT05556239
2025-12-08
STAY-STRONG
Rigshospitalet, Denmark
Phase NA
Completed
42 enrolled